Caprion

Accelerating precision medicine™

Press Release

Caprion Announces Completion of Phase I Clinical Studies for its Shigatoxin-producing E. coli Therapy

Montreal, Canada - September 19, 2006 - Caprion Pharmaceuticals Inc. announced today the completion of Phase I studies for Shigamabs®, its therapeutic product currently in human clinical trials for the treatment of Shigatoxin-producing E. coli infections.

Infections by Shigatoxin-producing E. coli (STEC), including the O157:H7 strain involved in the current US outbreak, cause severe clinical symptoms such as hemorrhagic colitis, thrombocytopenia, hemolytic anemia and hemolytic uremic syndrome in up to 60% of all infected patients, and are potentially lethal in the most severe cases. Serious complications are most frequent in young children and the elderly. There are no treatments currently available for STEC infections.

The safety and tolerability of Caprion's anti-toxin antibodies were evaluated in 40 healthy adult volunteers. Shigamabs® were shown to be safe and well tolerated when given individually or concomitantly in 3 clinical studies conducted over the last 4 years at major medical centers in the US and Canada. Detailed results will be presented at the upcoming VTEC 2006 meeting in Melbourne, Australia.
Caprion anticipates moving Shigamabs® into a European Union and North American pivotal trial in 2007 pending final regulatory review.

About Caprion Pharmaceuticals Inc.

Caprion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical-stage programs include: (i) Shigamabs®, a product for the treatment of Shigatoxin-producing bacterial infections, and (ii) CAP-232, a peptide with broad applicability in several oncology indications. Additionally, CellCarta®, Caprion's proprietary proteomics technology, provides Caprion with an effective means to identify novel drug targets, predict which therapeutics may be safer and more efficacious and, in certain cases, identify which patients may benefit most from a particular therapy.


FOR MORE INFORMATION CONTACT:
Caprion Pharmaceuticals Inc.
Cindy Dandurand
(514) 228-3645

Back to news list


Caprion

Accreditations & Certifications

CAP accreditation and CLIA certification

CAP Accredited

Headquarters

+1 514.360.3600
+1 877.776.3443
141 President Kennedy Ave., Suite SB-5658
Montreal, Quebec
CANADA

USA

Primity Bio
48383 Fremont Blvd
Suite 118
Fremont, CA 94538
Tel.: +1 858.229.2529

Serametrix
2235 Farraday Ave,Suite N,
Carlsbad, CA, 92008, USA
Tel: +1 760 652 4060

HistoGeneX
1331 W 75th St #401,
Naperville, IL 60540, USA
Tel: +1 630-473-6655
info@histogenex.com

AUSTRALIA

Serametrix Party Limited
Suite 4/54-60 Briggs Street
Camperdown, NSW, 2050
Australia
+61 2 9168 5908

EUROPE

Caprion Biosciences Inc.
+32 (0) 71 96 23 36
8 rue Adrienne Bolland
6041 Gosselies
BELGIUM

Serametrix
Unit 22, Surrey Technology Centre,
40 Occam Road,
Guildford, Surrey, UK
GU2 7YG
Tel: +44 1483 685599

Antwerp, Belgium
HistoGeneX
Sint-Bavostraat 78
2610 Antwerpen (Wilrijk)
Belgium
Tel: +32 3 50 20 500
Sample Reception: +32 3 50 20 620
Shipments: +32 3 50 20 625

CANADA LAB

201 President Kennedy Ave., Suite PK-3900
Montreal, Quebec
CANADA
+1 514.360.3600
+1 877.776.3443



Follow us

        

Contact

+1 877.776.3443

info@caprion.com